Astellas Drug Patent Portfolio
Astellas owns 12 orange book drugs protected by 67 US patents with Adenoscan having the least patent protection, holding only 1 patent. And Lexiscan with maximum patent protection, holding 19 patents. Given below is the list of Astellas's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12161628 | Combination therapy | 23 Feb, 2037 | Active |
| US10786500 | Stable pharmaceutical composition for oral administration | 01 Jul, 2036 | Active |
| US11938130 | Stable pharmaceutical composition for oral administration | 01 Jul, 2036 | Active |
| US11938131 | Stable pharmaceutical composition for oral administration | 01 Jul, 2036 | Active |
| US11938132 | Stable pharmaceutical composition for oral administration | 01 Jul, 2036 | Active |
| US11938133 | Stable pharmaceutical composition for oral administration | 01 Jul, 2036 | Active |
| US11944620 | Stable pharmaceutical composition for oral administration | 01 Jul, 2036 | Active |
| US11273171 | Methods for treating or preventing ophthalmological conditions | 11 Jul, 2034 | Active |
| US11491176 | Methods for treating or preventing ophthalmological conditions | 11 Jul, 2034 | Active |
| US12016875 | Methods for treating or preventing ophthalmological conditions | 11 Jul, 2034 | Active |
| US10836768 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | 28 Mar, 2034 | Active |
| US9422299 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | 28 Mar, 2034 | Active |
| US9987274 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | 28 Mar, 2034 | Active |
| US11839689 | Formulations of enzalutamide | 11 Sep, 2033 | Active |
| US8969336 | Diamino heterocyclic carboxamide compound | 28 Nov, 2032 | Active |
| US9918970 | Pharmaceutical composition comprising solifenacin | 18 May, 2031 | Active |
| US8871761 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | 04 Apr, 2031 | Active |
| US9487491 | Diamino heterocyclic carboxamide compound | 28 Jul, 2030 | Active |
| US10206879 | Active ingredient containing stabilised solid forms and method for the production thereof | 14 Mar, 2028 | Active |
| US10603280 | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof | 14 Mar, 2028 | Active |
| US10206879 | Active ingredient containing stabilised solid forms and method for the production thereof | 14 Sep, 2027 | Active |
| US10603280 | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof | 14 Sep, 2027 | Active |
| US7709517 | Diarylhydantoin compounds | 13 Aug, 2027 | Active |
| US8106183 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | 02 Feb, 2027 | Active |
| US9085601 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | 02 Feb, 2027 | Active |
| USRE47301 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | 02 Feb, 2027 | Active |
| US8236773 | Aptamer therapeutics useful in the treatment of complement-related disorders | 11 Nov, 2026 | Active |
| US8183274 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | 24 Aug, 2026 | Active |
| US9126941 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | 15 May, 2026 | Active |
| US6812238 | N-substituted carbamoyloxyalkyl-azolium derivatives | 30 Apr, 2026 | Active |
| US7579456 | Aptamer therapeutics useful in the treatment of complement-related disorders | 14 Feb, 2026 | Active |
| US9617546 | Aptamer therapeutics useful in the treatment of complement-related disorders | 14 Feb, 2026 | Active |
| US10812238 | Configurable reference signals | 31 Oct, 2025 | Active |
| US6812238 | N-substituted carbamoyloxyalkyl-azolium derivatives | 31 Oct, 2025 | Active |
| US10947544 | Aptamer therapeutics useful in the treatment of complement-related disorders | 14 Feb, 2025 | Expired |
| US7538211 | Aptamer therapeutics useful in the treatment of complement-related disorders | 14 Feb, 2025 | Expired |
| US7803931 | Aptamer therapeutics useful in the treatment of complement-related disorders | 14 Feb, 2025 | Expired |
| US6403567 | N-pyrazole A2A adenosine receptor agonists | 10 Apr, 2022 | Expired |
| US6774104 | Stabilized pharmaceutical composition in lyophilized form | 08 Jul, 2021 | Expired |
| US6774104 | Stabilized pharmaceutical composition in lyophilized form | 08 Jan, 2021 | Expired |
| US7459561 | N-substituted carbamoyloxyalkyl-azolium derivatives | 31 Oct, 2020 | Expired |
| US6642210 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists | 22 Jun, 2019 | Expired |
| US7144872 | N-pyrazole A2A receptor agonists | 22 Jun, 2019 | Expired |
| US7183264 | N-pyrazole A2A receptor agonists | 22 Jun, 2019 | Expired |
| US7582617 | Myocardial perfusion imaging method | 22 Jun, 2019 | Expired |
| US7655636 | Use of A2A adenosine receptor agonists | 22 Jun, 2019 | Expired |
| US7655637 | N-pyrazole A2A receptor agonists | 22 Jun, 2019 | Expired |
| US7683037 | Myocardial perfusion imaging method | 22 Jun, 2019 | Expired |
| US8106029 | Use of A2A adenosine receptor agonists | 22 Jun, 2019 | Expired |
| US8133879 | Myocardial perfusion imaging methods and compositions | 22 Jun, 2019 | Expired |
| US8183226 | Myocardial perfusion imaging method | 22 Jun, 2019 | Expired |
| US8470801 | Myocardial perfusion imaging methods and compositions | 22 Jun, 2019 | Expired |
| US8536150 | Methods of myocardial perfusion imaging | 22 Jun, 2019 | Expired |
| US9045519 | N-pyrazole A2A receptor agonists | 22 Jun, 2019 | Expired |
| US9289446 | Myocardial perfusion imaging methods and compositions | 22 Jun, 2019 | Expired |
| USRE47351 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists | 22 Jun, 2019 | Expired |
| US6017927 | Quinuclidine derivatives and medicinal composition thereof | 19 May, 2019 | Expired |
| US6440458 | Sustained release preparations | 25 Mar, 2019 | Expired |
| US6576259 | Sustained release formulations containing tacrolimus | 25 Mar, 2019 | Expired |
| US6884433 | Sustained release formulation containing tacrolimus | 25 Mar, 2019 | Expired |
| US8551522 | Sustained-release formulation | 25 Mar, 2019 | Expired |
| US6107458 | Cyclic hexapeptides having antibiotic activity | 16 Mar, 2019 | Expired |
| US6017927 | Quinuclidine derivatives and medicinal composition thereof | 19 Nov, 2018 | Expired |
| US5965156 | Amphotericin B liposome preparation | 12 Oct, 2016 | Expired |
| US5874104 | Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics | 23 Feb, 2016 | Expired |
| US6265536 | Cyclic hexapeptides having antibiotic activity | 29 Sep, 2015 | Expired |
| US5731296 | Selective vasodilation by continuous adenosine infusion | 24 Mar, 2015 | Expired |
Latest Legal Activities on Astellas's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Astellas.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 May, 2024 | US10836768 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Apr, 2024 | US9487491 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Apr, 2024 | US10812238 |
| Recordation of Patent eGrant | 02 Apr, 2024 | US11944620 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Apr, 2024 | US11944620 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Apr, 2024 | US11944620 |
| Mail Patent eGrant Notification | 02 Apr, 2024 | US11944620 |
|
Email Notification
Critical
| 02 Apr, 2024 | US11944620 |
| Patent eGrant Notification | 02 Apr, 2024 | US11944620 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Mar, 2024 | US10786500 |
| Patent eGrant Notification | 26 Mar, 2024 | US11938133 |
| Initial letter Re: PTE Application to regulating agency | 26 Mar, 2024 | US8236773 |
| Recordation of Patent eGrant | 26 Mar, 2024 | US11938133 |
|
Email Notification
Critical
| 26 Mar, 2024 | US11938131 |
| Initial letter Re: PTE Application to regulating agency | 26 Mar, 2024 | US9617546 |
Astellas Drug Patents' Oppositions Filed in EPO
Astellas drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 03, 2010, by Basilea Pharmaceutica International Ag. This opposition was filed on patent number EP07802308A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11184401A | Dec, 2015 | Generics (U.K.) Limited | Revoked |
| EP06748863A | Oct, 2012 | Fickert, Stefan | Patent maintained as amended |
| EP07802308A | Dec, 2010 | Basilea Pharmaceutica International AG | Patent maintained as amended |
Astellas's Family Patents
Astellas Drug List
Given below is the complete list of Astellas's drugs and the patents protecting them.
1. Adenoscan
Adenoscan is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5731296 | Selective vasodilation by continuous adenosine infusion |
24 Mar, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adenoscan's drug page
2. Ambisome
Ambisome is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5965156 | Amphotericin B liposome preparation |
12 Oct, 2016
(8 years ago)
| Expired |
| US5874104 | Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics |
23 Feb, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ambisome's drug page
3. Astagraf Xl
Astagraf Xl is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6440458 | Sustained release preparations |
25 Mar, 2019
(6 years ago)
| Expired |
| US6576259 | Sustained release formulations containing tacrolimus |
25 Mar, 2019
(6 years ago)
| Expired |
| US6884433 | Sustained release formulation containing tacrolimus |
25 Mar, 2019
(6 years ago)
| Expired |
| US8551522 | Sustained-release formulation |
25 Mar, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astagraf Xl's drug page
4. Cresemba
Cresemba is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10206879
(Pediatric)
| Active ingredient containing stabilised solid forms and method for the production thereof |
14 Mar, 2028
(2 years from now)
| Active |
| US10603280
(Pediatric)
| Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
14 Mar, 2028
(2 years from now)
| Active |
| US10206879 | Active ingredient containing stabilised solid forms and method for the production thereof |
14 Sep, 2027
(2 years from now)
| Active |
| US10603280 | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
14 Sep, 2027
(2 years from now)
| Active |
| US6812238
(Pediatric)
| N-substituted carbamoyloxyalkyl-azolium derivatives |
30 Apr, 2026
(11 months from now)
| Active |
| US10812238 | Configurable reference signals |
31 Oct, 2025
(5 months from now)
| Active |
| US6812238 | N-substituted carbamoyloxyalkyl-azolium derivatives |
31 Oct, 2025
(5 months from now)
| Active |
| US7459561 | N-substituted carbamoyloxyalkyl-azolium derivatives |
31 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cresemba's drug page
5. Izervay
Izervay is protected by 9 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273171 | Methods for treating or preventing ophthalmological conditions |
11 Jul, 2034
(9 years from now)
| Active |
| US11491176 | Methods for treating or preventing ophthalmological conditions |
11 Jul, 2034
(9 years from now)
| Active |
| US12016875 | Methods for treating or preventing ophthalmological conditions |
11 Jul, 2034
(9 years from now)
| Active |
| US8236773 | Aptamer therapeutics useful in the treatment of complement-related disorders |
11 Nov, 2026
(1 year, 6 months from now)
| Active |
| US7579456 | Aptamer therapeutics useful in the treatment of complement-related disorders |
14 Feb, 2026
(9 months from now)
| Active |
| US9617546 | Aptamer therapeutics useful in the treatment of complement-related disorders |
14 Feb, 2026
(9 months from now)
| Active |
| US10947544 | Aptamer therapeutics useful in the treatment of complement-related disorders |
14 Feb, 2025
(2 months ago)
| Expired |
| US7538211 | Aptamer therapeutics useful in the treatment of complement-related disorders |
14 Feb, 2025
(2 months ago)
| Expired |
| US7803931 | Aptamer therapeutics useful in the treatment of complement-related disorders |
14 Feb, 2025
(2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Izervay's drug page
Explore Our Curated Drug Screens
6. Lexiscan
Lexiscan is protected by 19 patents, out of which 16 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8106183 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
02 Feb, 2027
(1 year, 8 months from now)
| Active |
| US9085601 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
02 Feb, 2027
(1 year, 8 months from now)
| Active |
| USRE47301 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
02 Feb, 2027
(1 year, 8 months from now)
| Active |
| US6403567 | N-pyrazole A2A adenosine receptor agonists |
10 Apr, 2022
(3 years ago)
| Expired |
| US6642210 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US7144872 | N-pyrazole A2A receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US7183264 | N-pyrazole A2A receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US7582617 | Myocardial perfusion imaging method |
22 Jun, 2019
(5 years ago)
| Expired |
| US7655636 | Use of A2A adenosine receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US7655637 | N-pyrazole A2A receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US7683037 | Myocardial perfusion imaging method |
22 Jun, 2019
(5 years ago)
| Expired |
| US8106029 | Use of A2A adenosine receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US8133879 | Myocardial perfusion imaging methods and compositions |
22 Jun, 2019
(5 years ago)
| Expired |
| US8183226 | Myocardial perfusion imaging method |
22 Jun, 2019
(5 years ago)
| Expired |
| US8470801 | Myocardial perfusion imaging methods and compositions |
22 Jun, 2019
(5 years ago)
| Expired |
| US8536150 | Methods of myocardial perfusion imaging |
22 Jun, 2019
(5 years ago)
| Expired |
| US9045519 | N-pyrazole A2A receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
| US9289446 | Myocardial perfusion imaging methods and compositions |
22 Jun, 2019
(5 years ago)
| Expired |
| USRE47351 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
22 Jun, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexiscan's drug page
7. Mycamine
Mycamine is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6774104
(Pediatric)
| Stabilized pharmaceutical composition in lyophilized form |
08 Jul, 2021
(3 years ago)
| Expired |
| US6774104 | Stabilized pharmaceutical composition in lyophilized form |
08 Jan, 2021
(4 years ago)
| Expired |
| US6107458 | Cyclic hexapeptides having antibiotic activity |
16 Mar, 2019
(6 years ago)
| Expired |
| US6265536 | Cyclic hexapeptides having antibiotic activity |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mycamine's drug page
8. Veozah
Veozah is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10836768 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
28 Mar, 2034
(8 years from now)
| Active |
| US9422299 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
28 Mar, 2034
(8 years from now)
| Active |
| US9987274 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
28 Mar, 2034
(8 years from now)
| Active |
| US8871761 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
04 Apr, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veozah's drug page
9. Vesicare
Vesicare is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6017927
(Pediatric)
| Quinuclidine derivatives and medicinal composition thereof |
19 May, 2019
(5 years ago)
| Expired |
| US6017927 | Quinuclidine derivatives and medicinal composition thereof |
19 Nov, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vesicare's drug page
10. Vesicare Ls
Vesicare Ls is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9918970 | Pharmaceutical composition comprising solifenacin |
18 May, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vesicare Ls's drug page
11. Xospata
Xospata is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10786500 | Stable pharmaceutical composition for oral administration |
01 Jul, 2036
(11 years from now)
| Active |
| US11938130 | Stable pharmaceutical composition for oral administration |
01 Jul, 2036
(11 years from now)
| Active |
| US11938131 | Stable pharmaceutical composition for oral administration |
01 Jul, 2036
(11 years from now)
| Active |
| US11938132 | Stable pharmaceutical composition for oral administration |
01 Jul, 2036
(11 years from now)
| Active |
| US11938133 | Stable pharmaceutical composition for oral administration |
01 Jul, 2036
(11 years from now)
| Active |
| US11944620 | Stable pharmaceutical composition for oral administration |
01 Jul, 2036
(11 years from now)
| Active |
| US8969336 | Diamino heterocyclic carboxamide compound |
28 Nov, 2032
(7 years from now)
| Active |
| US9487491 | Diamino heterocyclic carboxamide compound |
28 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xospata's drug page
12. Xtandi
Xtandi is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12161628 | Combination therapy |
23 Feb, 2037
(11 years from now)
| Active |
| US11839689 | Formulations of enzalutamide |
11 Sep, 2033
(8 years from now)
| Active |
| US7709517 | Diarylhydantoin compounds |
13 Aug, 2027
(2 years from now)
| Active |
| US8183274 | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
24 Aug, 2026
(1 year, 3 months from now)
| Active |
| US9126941 | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
15 May, 2026
(1 year, 5 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xtandi's drug page